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Table VI. Logistics regression report 
Response variable: Correct prediction 
Parameter estimation section 
Regression 
Variable coefficient 
Intercept 3.323 
Days (in hospital) 0.005 
Blunt (1 = blunt) 0.054 
Age -0.019 
Hospital (1 = JH) -0.463 
Helicopter (1 =helicopter) -1.300 
JH ~johannesburg Hospital. 
Standard Probability 
error level 
0.510 0.000 
0.010 0.602 
0.400 0.893 
0.011 0.076 
0.333 0.164 
0.400 0.001 
highly significant variable, only the patient's age is possibly 
significant (P = 0.076). Not surprisingly, the older the patient 
the less likely the TRISS methodology is to predict the 
probability of survival or death correctly. 
CONCLUSION 
Helicopters clearly deserve a place in the emergency care of 
trauma victims. However, this is only one link in the chain that 
will ultimately lead to either death or survival. For it to be 
successful, it must link reliable, efficient emergency medical 
services (road-based) and effective trauma centres that are 
staffed appropriately with a committed team of health care 
professionals. If used appropriately there appears to be little 
doubt that these expensive machines can play an important 
role in preventing certain unnecessary deaths while reducing 
costs for both individuals and health care facilities. 8·' 
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SPECIAL ARTICLE 
EXPLORING THE COSTS OF A 
LIMITED PUBLIC SECTOR 
ANTIRETROVIRAL TREATMENT 
PROGRAMME IN SOUTH AFRICA 
Andrew Boulle, Christopher Kenyon, Jolene Skordis, Robin 
Wood 
Background. The role of antiretroviral treatment for adults in 
the pubic sector in South Africa is debated with little 
consideration of programme choices that could impact on the 
cost-effectiveness of the intervention. This study seeks to 
explore the impact of these programme choices at an 
individual level, as well as explore the total cost of a rationed 
national public sector antiretroviral treatment programme. 
Methods. Eight scenarios were modelled of limited national 
treatment programmes over the next 5 years, reflecting 
different programme design choices. The individual cost~ 
effectiveness of these scenarios were compared. The total 
costs of the most cost-effective scenario were·calculated, and 
the potential for savings in other areas of health care 
utilisation was explored. 
Results. The direct programme costs per life-year saved 
varied between scenarios from RS 923 to Rll 829. All the 
costs of the most cost-effective scenario could potentially be 
offset depending on assumptions of health care access and 
utilisation. The total programme costs for the most cost-
effective scenario in 2007 with 107 000 people on treatment 
are around R409 million. 
Conclusion. Specific policy choices could almost double the 
number of people who could benefit from an investment in a 
limited national antiretroviral treatment programme. Such a · · 
programme is affordable within current resource constraints. 
The consideration of antiretroviral treatment calls for a 
unique public health approach to the rationing of health 
services in the public sector. 
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Table I. Description of modelled scenarios and sensitivity analysis scenarios 
The cost per life-year gained is presented at 5 years for the following eightintervention options: 
(A) Baseline (generic medication, baseline testing and visit costs) 
(B) Optional (higher proportion of doctor visits, and additional viral load testing) 
(C) Patent medicine pricing scenario 
(D) Second-line treatment offered to 50% of those with virological failure on first-line treatment at generic medicine prices 
(E) Second-line treatment offered to 75% with virological failure ori firstcline treatment at generic medicine prices 
(F) Patent medicine pricing and optional testing and consultation schedule (B & C combined) 
(G) Pat~ntmedicine pricing, optional testing and consultation schedule, and 50% of those failing first line offered second-line treatment 
(B, C & D combined) 
(H) Second-line treatment offered to 50% of those with virological failure on first-line treatment at generic medicine prices, with optional 
testing and consultation parameters (B & D combined) 
In addition, sensitivity analyses are produced for the following seven changes in assumptions: 
Sl. (A) with no discount over time for medicines 
52. (A) with a·15% per annum discount over time for medicines for 3 years, followed by 7:5% annually 
53. (A) with no additional costs for each consultation compared to current services 
54. (A) with 2.5 times the Current consultation costs for each corisultation 
SS. (A) with increased mean survival on first-line treatment to 3.6 years (from 2.68) 
56. (DJ with increased mean survival on first line to 3.6 ye<1rs and 7.41 years for consecutive regimens 
57. (A) With no provision for visits to the new services for people who are not on ARVs, and 
SS. (D) with no discount over time for medicines 
Whereas the role for antiretroviral therapy (ART) for HIV has 
been an issue for scientific and public debate in South Africa, a 
number of middle-income and poor countries have already 
initiated treatment programmes in spite of resource constraints 
(Brazil, Chile, Thailand, Nigeria, Senegal, Cote D'Ivoire). The 
recent publication by the World Health Organisation1 of 
guidelines for the scaling up of antiretroviral treatment 
programmes is indicative of both a convergence of clinical 
thinking and the increasing pressure on health care systems to 
provide antiretroviral interventions. 
In addition to the survival and quality of life benefits for 
individual patients,'·' many authors have pointed to the 
synergies between antiretroviral treatment programmes and 
preventive strategies.'·' Others have compellingly described the 
role extended HIV survival could have in reducing the burden 
on society and preserving our human and social 
infrastructure. 4•8 
The following model costs a rationed national antiretroviral 
treatment programme for adult South Africans that could 
conceivably begin in 2002. From the perspective of the public 
health system, we explore the relative cost-effectiveness of a 
number of ART-related policy options and the overall resource 
mfJ implications of a limited national antiretroviral treatment 
, programme. 
METHODS 
Service model 
The approach to costing ART provision is based on an 
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emerging service model in which: 
• Specific HIV I AIDS services are required to develop the 
relationships between patients and clinicians, to ensure 
continuity of care, and to provide a mechanism through 
which patients can be evaluated for potential enrollment 
onto an ART programme. 
• Consequent on meeting predetermined eligibility criteria, 
which are a combination of clinical and (possibly) social 
assessment,' patients are considered eligible for ART around 
the time that they become AIDS symptomatic. 
• After commencing treatment, patients are managed through 
the HIV I AIDS service, but still attend regular services for 
other routine and acute care. 
Numbers on treatment 
A spreadsheet model with eight scenarios (Table I) was used to 
anticipate the numbers of people on antiretroviral treatment 
over the next 10 years. In the model, the number of new 
patients receiving treatment was gradually increased over 5 
years. The cumulative number of people surviving on 
treatment in the model by the middle of 2007 varied between 
scenarios from 106 911 to 117 621, depending on survival 
assumptions and whether or not second-line treatment was 
offered to a proportion of those failing the first-line regimen 
(Fig. 1). 
Those on treatment were stratified into a number of 
subgroups, reflecting those on a first-line regimen, those on a 
second-line regimen, and those failing treatment. The first 6 
months of a new regimen were distinguished from the 
remaining time on the regimen. The model was run for a 
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,------
A: Baseline scenario D: 50% accessing second line 
substitute for individual 
medicines, the price of the 
combination tablet was included. - 250 000 Adult Failing ARV - 250 000 c:J Adult Failin~ ARV /::d c c:J c ~ 200 000 c:J Adult ARV 1st line - ~ 200 000 ~ Adult ARV nd line 
'" 
_._ New ARV Total / 1ij C:::J New ARV 1st line Future price changes are another 
important variable in anticipating 
medicine costs. The model 
presented assumes an annual price 
reduction in real terms of 10% per 
year for the first 3 years and 5% 
annually thereafter. Sensitivity 
analysis explores the impact of no 
reduction in price and a 15% initial 
reduction (for the first 3 years) 
followed by 7.5% per annum. 
_!g 150 000 _g: 150 000 _._ New ARVTotal 
c ~ c ~ ~ 100 000 g ~ 100 000 ~ (]) "' _o .a E 50 000 ~ E 50000 ~ ::l ::l z z 0 0 
C') .... U) 
"' 
1'- co 0) 0 ~ C\J C') .... L!) 
"' 
1'- co 0) 0 ~ C\J 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
C\1 C\1 C\1 C\J C\1 C\1 C\1 C\J C\J C\1 C\J C\1 C\J C\1 C\1 C\1 C\1 C\1 C\J C\1 
Mrd year 2003 2004 2005 2006 2007 
A: Baseline 3130 10403 27 301 59812 106911 
0 D: 50% accessing second line 3179 10586 27930 61 420 110361 '§ 
c E: 75% accessing second line 3 204 10677 28249 62 254 112181 (]) 
() 85: A, with median survival 4 years on first line 3211 10 836 28 691 63367 114491 (/) 
86: D, with median survivals 4 and 6.5 years 3253 10982 29224 64 782 117621 
Fig. 1. Numbers on treatment by category of treatment in modelled scenarios. Laboratory monitoring 
further 5 years with constant assumptions in order to explore 
the medium-term impact of deferring costs. By 2007 the 
numbers of people accessing treatment in the model could 
represent 10% of those becoming AIDS-symptomatic that year 
(compared with estimates of adult deaths in the subsequent 2 
years"'). The combined impact on new init!ctions of extended 
survival, reduced viral load and altered behaviour for those on 
treatment was assumed to be neutral compared with a no-
treatment scenario. Additional or averted new infections are 
likely to have little impact on the total direct treatment costs in 
the timeframe of this analysis. 
Direct programme costs 
Medicines 
The biggest cost-driver of ART is undoubtedly the medicine 
costs. In this model, the limited number of medicines selected 
is sufficient for a single regimen or for two independent 
regimens, while still sufficiently restricted to limit costs in both 
the generic and patent pricing scenarios. It is assumed that all 
rationally selected starting regimens have equivalent treatment 
outcomes.11 
The estimated proportion of patients likely to switch from 
any single medicine due to intolerance is based on the 
experience to date in Khayelitsha12 validated by HIV clinicians. 
In cases of single-medicine changes, the first 6 months of 
treatment are apportioned to the starting medicine, while the 
remaining time on the regimen is apportioned to the medicine 
to which the patient changes. In effect virological failure and 
intolerance are modelled separately, with the crude assumption 
that 6 months is the average time at which a medicine is 
changed for reasons of intolerance. It was necessary to include 
intolerance-driven individual medicine switches within first-
and second-line regimens as they impact significantly on 
overall medicine costs in the baseline scenario (where generic 
pricing is utilised). Where a combination tablet could 
Based on the WHO 
recommendations/ the model incorporates two testing 
scenarios. The first provides for all tests (including a twice-
yearly CD4 count and a CD4 count before enrolment) except 
for viral load testing. The second is an optional scenario in 
which viral load tests and CD4 counts are conducted three 
times a year. 13 
Visit costs for the antiretroviral treatment programme 
Allowing that consultation costs (including additional staff 
training) may be higher than for standard primary care 
consultations, a factor of 1.5 is applied to the average cost of a 
primary care consultation in the Western Cape metropole 
(where there are doctor- and nurse-driven services). This factor 
is varied between 1 and 2.5 in the sensitivity analysis. 
The visit schedule applied is that used in the current Medicin 
Sans Frontieres treatment protocol' to estimate the additional 
visits required as a result of ART. Again two scenarios are 
built; one in which a proportion of the visits are at a lower cost 
structure as the visit is principally to ensure adherence and 
dispense medicines, and another where the majority of the 
visits are with a doctor. 
Provision is also made for visits to HIV I AIDS services by a 
proportion of HIV-infected people in WHO clinical stage 3. 
This proportion is set equal to the proportion of patients 
aq:essing treatment when becoming AIDS-symptomatic. The 
model assumes an average of 3 visits per year for those not on 
antiretrovirals but attending the HIV I AIDS services as a 
prelude to possible enrolment in an ART programme. These 
visits are costed at the existing clinic consultation costs, and m:g 
form a substantial component of the workload. 
Anticipating the individual benefits of treatment 
The survival benefits of ART are not yet fully described. 
Published data at 3 years since the initiation of therapy, 
however, suggest a remarkable reduction in the anticipated 
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mortality.'·' UN AIDS currently recommend that a survival 
benefit of 5 - 7 years be used for HIV modelling in rich 
countries." Early indications suggest that a rationed programme 
in South Africa is likely to have comparable benefits to rich 
countries, taking into account baseline immunological 
characteristics at the onset of treatmenU5•16 The model below 
uses a median survival from initiating treatment of 4.5 years if 
two regimens are offered (weibull distribution, mean of 6.06 
years of which the benefit is 4.46 years). The model assumes that 
treatment is failing for a period at the end of treatment of 
equivalent duration to WHO stage 4. It is further assumed that, 
of the survival benefit, 60% is derived from the first regimen, 
and the remainder from an alternative regimen. For the 
scenarios in which second-line treatment is included, it is 
assumed that not everyone in whom a first regimen fails will be 
offered a second regimen, either because they have exhausted 
their affordable treatment options through intolerance-driven 
individual medicine changes, or because they do not meet 
0%, 50%, or 75% 
8 
additional eligibility criteria for second-line treatment. 
The life-years gained derive directly from the survival 
benefit assumptions, and are calculated as life-years gained per 
year on treatment while treatment is not failing (Fig. 2). 
Benefits on broader health care utilisation 
Although antiretroviral treatment does not prevent the 
eventual morbidity and associated health care utilisation that 
occurs in the terminal stages of HIV infection, this utilisation is 
deferred by the duration of the survival benefit. Within the 
realistic timeframes of any planning exercise of this nature, this 
deferment could result in a real benefit to the health care 
system. The key contributors to the cost saving are the 
principal cost drivers of hospital inpatient days, ambulatory 
consultations and tuberculosis treatment. No discounting was 
applied to deferred costs. 
The estimates used (Table II) are similar to those used in 
other HIV costing studies.l7,l8 
D E 
Second line non-failing. mean 1.78 years: Failing treatment. mean 1.6 years 
c 
r---------------! - - - - - - - - - - -
1 · 10% First line non-failing, mean 2.68 years Failing treatment, mean 1.6 years 
A 
HIV infection until stage 4: Mean 7.5 · 9.1 years i siage 4-:-Meaii' 1-:-47-. 1.8 years 
Life years saved per non-failing year on treatment First line·. (B+C-A)/B ~ 1 Second line: (D+E-C)/D ~ 1 
Fig. 2. Survival and effectiveness assumptions. 
Table II. Cost and utilisation assumptions 
Utilisation Cost 
Units Stage 4 ARVFL ARVSL Failing Units Min. Max. 
Non-ARV HIV-related clinical costs 
Hospitalisation (1) Inpatient days 18.8 2.8 3.8 18.8 Inpatient day R530 R530 
Clinic consultations (2) Extra consults 11 2 2 11 Visit cost R73 R73 
Tuberculosis (3) Annual risk 36% 4% 4% 36% Treatment cost Rl560 R1560 
ARV-related costs 
ARV medicine costs (4) ARV utilisation 100% 100% 50% Annual cost R4612 R15 288 
ARV laboratory costs (5) Extra tests Yes Yes No Annual cost R457 R2 206 
ARV visit costs (6) Visits 12 12 3 Annual cost R821 R986 
(1 & 2) Utilisal)on assumptions the same as used in the study by.Abt and assodates," with a reduction in length of s.tay from .10 days to 8 days for stage 4 based on more recent 
inpatient studies. Clinic visits are calculated at the current price per consultation in primary health care services in Cape Town, and reflect excess visits ·as a result of HIV. Utilisation 
while on ARVs is premised on an 80% reduction in hospitalisation and clinic visits compared with stage 4. 
(3) Taken from cohort data in Cape 1own,'1 with additinnal assumption of relative risk of tuberculosis between stages 4. and 3 of 2, and relative prevalence between stages 3 and 4 of 2. 
Cost per completed treatment from Western Cape Department of Health, reflecting only a proportion (60%) of the DOTS-related costs so as not to double-count the tuberculosis-related 
PHC1 medicine and hospitalisation costs. 
(4) Starting regimen i~ generic scenarios is T'riomune (D4T, 3TC, NVP, $295/year), with 57% still on Triomune by 6 m011ths due to intolerance-driven individual medicine switches. 
Second-line regimen for generic scenarios is AZT, DDI and !NV /RTV. The same regimen is the cheapest patented regimen as well (used here as individual drugs) unless DDI and D4T 
are combined. Medicine costs calculated for on average half of the time after treatment has started failing. It is hoped that LPV /RTV could replace !NV /RTV with little impact on costs 
if preferential pridng is obtained. 
(5)Range of tests depending on individua\1\\edicines include FBC, diff., creatinine, ALT, cholesterol, glucose and amylase. 1\vice·yearly CD4 counts (R83 per test) are included 
additionally in pragmatic scenarios. Thrice-yearly viral loads (R550 per test) and CD4 counts are included only in the 'optional' scenarios. 
(6) 80% of visits in the 'optional' scenarios, and 60% in the remaining scenarios, are with a doctor. The non-doctor visits_are with a nurse and/ or counsellor, and are principally to 
support adherence and dispense medicines, Doctor visit.;; are calc~lated_ at the _current price per consultation in -primary health care services in Cape Town, wi~h an additional cost of 
50% varied to an additional150% in sensitivity analysis. Non~doctor visits are costed at 75% of the reference costs, 
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RESULTS 
Direct treatment costs 
The direct costs of treatment for the baseline (A and D) 
scenarios were stratified by regimen and by the first 6 months 
on each regimen (Fig. 3). The first 6 months of treatment are 
disproportionately expensive compared with the subsequent 
annual costs, especially with respect to laboratory and 
consultation costs. The differential between first-line and 
second-line medicine prices when accessing generic medicines 
is clearly evident. The costs per treatment year (after the first 6 
months) vary between scenarios and regimens from R5 890 (A: 
first-line) to R15 288 (G: second-line). Medicine costs dominate 
expenditure across all scenarios and regimens. 
Cost per life-year gained 
The use of generic versus patented medicines is the single most 
important factor impacting on the costs per life-year gained at 
5 years (Table III). The cost per life-year gained is 48 -53% 
greater when patented medicine prices are utilised. Additional 
R12,000 
R10,000 
~ 
RB,OOO -
R6,000 -
F== 
-
~ r----- -R4,000 
~ R2,000 r l - r----- -RO 
First line, initial First line Second line Second line 
6 months annually initial 6 months annually 
D Consultations R931 R821 R767 R821 
1!1 Laboratory R789 R457 R724 R473 
D Medicines R1,649 R4,612 R4,704 R8,933 
Total R3,368 R5,890 R6,195 R10,227 
Changing costs for baseline (A) scenario based on regimen 
and duration on regimen, 2002 prices 
Differential costs between scenarios, for the first-line regimen 
following the initial 6 months of treatment, 2002 prices 
Fig. 3. Direct costs at an individual/eve/ for antiretroviral 
interventions. 
testing and switching most of the consultations to doctors 
increased costs by a further 45%. Combining patented 
medicines with optional laboratory monitoring and 
consultation schedules yielded a 99% increase in the cost per 
life-year saved (F). 
In those scenarios where second-line treatment is included at 
generic prices (D and E), the marginal cost per life-year saved 
when adding this treatment is 36 - 39% higher than the baseline 
cost (A: first-line only). 
Sensitivity analysis reinforced the pivotal role of assumed 
changes in future medicine pricing (Sl and 52: 23% increase in 
the baseline cost per life-year saved over 5 years if no price 
reductions). It also demonstrated the relatively small impact of 
changing assumptions on the services required before 
enrolment (57), the cost-structure for consultations (53 and 54), 
or the duration of the survival benefit on treatment (55 and 56). 
Total costs and potential resource savings as a result 
of deferred treatment 
In the most cost-effective scenario, the total direct costs of a 
programme of this size are estimated to be R409 million in the 
year 2006 - 2007. Taking into account the deferred 
hospitalisation and consultation costs for those on ART, there is 
a considerable impact on resource utilisation. When quantified 
financially over 5 years, this covers the cost of antiretroviral 
treatment (135% of direct programme costs averted). At 10 
years some of the deferred costs have re-entered the system, 
reflected by a reduction in cumulative savings as a percentage 
of the direct intervention costs over this period (90% of 
intervention costs). 
DISCUSSION 
This exercise illustrates how policy choices impact on the 
benefits of a rationed ART programme and how those benefits 
are distributed. It is immediately apparent that accessing 
cheaper medicines could significantly extend the impact of 
such an intervention. We used generic pricing in our baseline 
scenario based on the sincere belief that it is a realistic policy 
option which has been successfully applied in a number of 
countries (generics of zidovudine and lamivudine have 
recently been registered by the Medicines Control Council, 
although they are still inaccessible due to patent restrictions). It 
is sometimes argued that medicine costs are over-emphasised. 
This analysis supports a strong emphasis on medicine costs. 
While the cost of monitoring patients on ART has fallen over 
the past year, some investigations (viral load testing in this 
analysis) remain prohibitively expensive for the benefit they 
add, and should not necessarily be an automatic component of 
a public sector programme until their costs are reduced. 
The marginal cost per life-year saved when adding second-
line treatment to the baseline scenario was considerably higher 
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Table III. Cost-effectiveness and sensitivity analyses 
%change %change 
from Marginal from first 
Cost/life-year baseline cost/life-year line 
A: Baseline RS 923 
B: Optional R8595 45 
C: Patent pricing R9 089 53 
D: 50% second-line access R6 082 3 R8 215 39 (1) 
E : 75% second-line access R6136 4 R8042 36 (2) 
F: B & C combined R11 761 99 
G: B, C & D combined Rll 829 100 R12 736 8 (3) 
H: B & D combined R8775 48 R11202 23 (4) 
Sensitivity analysis 
Sl: A with no medicine discount R7266 23 
52: A with medicine discounts 50% higher R5388 -9 
S3: A with no additional cost for consultations R5 571 -6 
S4: A with visit cost factor 2.5 R6627 12 
55: A with first-line survival4 years R5675 -4 
56: D with combined survival of 6.5 years R5 797 -2 R8184 44 (5) 
S7: A with no non-ARV visit costs R5 398 -9 
S8: D with no medicine discounts R7 528 27 R11 048 52 (6) 
(1 & 2) compared to A, (3) compared to F, (4) compared to B, (5) compared to SS, (6) compared to Sl. 
(39%) than the cost without this option. This increase is 
partially masked by the reductions in medicine prices over 
time, as those accessing second-line treatment are doing so a 
few years into the programme. One sensitivity analysis (58) 
demonstrates that the marginal increase could be as high as 
52% without the effect of the medicine price reductions. 
Although clinicians baulk at limiting ART to a single tier of 
therapy, the option of spreading a smaller benefit to a greater 
number of patients needs serious consideration, bearing in 
mind the additional health system implications of enrolling 
additional new patients. We are not necessarily advocating 
that only one tier of therapy be considered. A gradual 
implementation of ART would have relatively few people on 
second-line treatment by 5 years, with the total programme 
costs not being considerably more expensive than the baseline 
programme cost presented. It is also likely that the differential 
cost between first- and second-line treatment will reduce over 
time as a greater number of antiretrovirals are produced by 
generic manufacturers. If the price differential remains large 
and financial resource constraints are considered the limiting 
factor to more widespread treatment, and if maximal diffusion 
of treatment is a policy goal, then an examination of the 
marginal costs of second-line treatment will remain important. 
Even without offsets, the total costs of a programme of this 
size are a small fraction of anticipated health sector 
expenditure on HIV I AIDS. Although many may find the size 
of this programme unpalatably small, a programme that is 
approaching 100 000 people on treatment within 5 years would 
be a significant achievement. 
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This study has a number of limitations. Importantly, in the 
absence of an existing policy to provide antiretrovirals as 
treatment for adults in the public sector, it was necessary to 
piece together assumptions from many different sources. Some 
assumptions should be treated with great caution, in particular 
those anticipating health service utilisation in the absence of 
antiretroviral treatment. 
Although estimates of health care utilisation that derive from 
cohort studies may not apply to the whole population due to 
unequal access, it is likely that those who do access the ART 
programme would have been able to access clinical services 
had they not received the intervention. Given the huge excess 
demand for services, it is unlikely that averted utilisation will 
result in financial savings in any but the least-affected 
provinces, resulting instead in better quality of care for those 
who would otherwise be unable to access services. The re-
entry into the system of deferred utilisation only partially 
erodes these gains even at 10 years, and should not deter 
health planners from comprehensively responding to the 
immediate crisis. 
It has been demonstrated that with the correct policy choices, 
the cost of providing an ART intervention could be 
considerably cheaper per year of treatment than has been 
quoted by many of the studies that have deemed ART to be 
unaffordable. 17•19•20 It has been further demonstrated that the 
averted costs could result in savings that make the intervention 
cost-saving, or at least significantly more cost-effective than an 
examination of the direct costs yields. This is only from the 
perspective of the health sector without consideration of 
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possible synergistic prevention gains. Even with the averted 
costs factored in, when the modelled intervention is scaled up 
to cover much greater percentages of those in need, it demands 
extraordinary expenditures. How can a cost-saving 
intervention be unaffordable? 
The public health system is implicitly rationing services 
through reduced access to care, and the extent of this is likely 
to increase. A modelled ART programme that assumes more 
extensive access than is implicitly provided for non-ART 
services at present, will appear unaffordable even if it is cost-
saving at an individual level. 
CONCLUSIONS 
There are very clear policy choices, political and clinical, which 
for the same expenditure could double the number of people 
benefitting from a rationed ART programme. A programme 
that utilises generic medicines, is pragmatic with respect to 
laboratory monitoring and consultations, and maximises the 
diffusion of benefits, is the most cost-effective, and is 
considerably cheaper than many previous estimates suggest. 
Whereas we should strive to provide treatment to as many of 
those in need as possible through the future mobilisation of 
additional resources and campaigning for price reductions in 
medicines and laboratory tests, a rationed treatment 
programme is currently affordable within existing resource 
constraints, and would have enormous benefits. We should not 
make our provision of this intervention consequent on raising 
additional resources, and the decision to proceed could in fact 
aid our attempts to mobilise external financial resources. The 
public good resulting from the broader impact on prevention 
and morale, which is arguably one of the major benefits of 
introducing a rationed programme now, could be substantially 
realised with relatively small numbers on treatment. 
The present and anticipated HIV burden on the public health 
care system is such that rationing is inevitable, with the 
prospect of planning for a new intervention such as ART 
requiring us to be explicit about our inability to meet demand. 
This paper serves to highlight the need for a revised public 
health discourse around rationing to deal with the unique 
challenges faced in providing antiretroviral interventions 
where they are most needed. 
The assistance of Fareed Abdullah, Steve Andrews, Motassim 
Badri, Susan Cleary, Emmanuelle Davaiud, Rob Darrington, Eric 
Goemaere, Leigh Johnson, Anthony Kinghorn, Gary Maartens and 
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with gratitude. 
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